Expected rapid advances in CAR T and other cellular therapies may expand treatment options not only in cancer but also in ...

Orca Bio has disclosed $250 million in funding, flooding its balance sheet with cash to buoy preparations for the ...

The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...

Colleen Mabasa, a patient with multiple myeloma, discusses her CAR T-cell therapy journey and the pivotal role self-advocacy ...

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...

Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...

Formerly Somite AI, the rebranded company aims to broaden the regenerative medicine landscape by building AI models that ...

Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with ...

Some parts of our bodies bounce back from injury in fairly short order. The outer protective layer of the eye—called the ...

Burkitt's lymphoma is a rare and aggressive blood cancer characterized by a translocation of the MYC gene. It occurs most ...

A blood cancer diagnosis comes with a lot of new information and confusion ranging from blood tests and medical terminology to healthcare provider conversations and treatment considerations. Here’s ...

In patients with relapsed or refractory systemic lupus erythematosus, allogeneic CAR-NK cell therapy may offer a safe ...